Educational Symposium
Redefining the IgAN Paradigm: Early Detection, Targeted Immunotherapy, and Clinical Reality
October 23, 2026 | 12:45 PM - 01:45 PM
Location: Capitol Ballroom, Hyatt Regency Denver
Session Description
As the treatment of IgAN evolves, therapies targeting a proliferation-inducing ligand (APRIL) and B cell-activating factor (BAFF) are emerging as cornerstones of management. Leading experts discuss APRIL and BAFF dysregulation, the rise of predictive biomarkers beyond standard eGFR and proteinuria, and the need to incorporate patient-reported outcomes (PROs). This symposium highlights a holistic approach to care that integrates molecular innovation, clinical trial data, and recent international guidelines to develop a pragmatic strategy for long-term kidney preservation and improved quality of life.
Doors open around 12:30 p.m. Seating is limited and available on a first-come, first-served basis to fully paid Annual Meeting participants. When a room reaches capacity, ASN will close the room, and no other participants will be allowed to enter, regardless of how many exit.
Support is provided by an educational grant from Vera Therapeutics, Inc.
Learning Objective(s)
- Describe the roles of APRIL and BAFF dysregulation in IgAN progression and the rationale for targeting these ligands therapeutically
- Explain the utility of emerging predictive biomarkers as complements to eGFR and proteinuria for refining prognosis and assessing treatment response in IgAN
- Discuss strategies that integrate PROs into treatment decisions to support long-term kidney preservation and quality of life
Learning Pathway(s)
- Glomerular Diseases
- Pathology
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Targeting the Dual-Ligand Pathway: APRIL, BAFF, and the Shift Toward Predictive Biomarkers in IgAN Management
12:55 PM - 01:15 PM
- Incorporating PROs and Holistic Strategies to Improve Quality of Life in IgAN
01:15 PM - 01:35 PM
- Q&A
01:35 PM - 01:45 PM